Locations:
Search IconSearch
August 3, 2015/Cancer/News & Insight

Doing More Is Not Always Better

An NEJM Editorial

CTscanner_690x380

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Khorana inset_150X180

Alok Khorana, MD

How should a clinician respond when a patient presents with an unprovoked venous thromboembolism? Clots of indeterminant cause are common, and epidemiological studies have shown that some are associated with undiagnosed cancer. While an aggressive and extensive diagnostic workup might seem like a logical course, especially with a worried patient, does this “do-more” approach lead to earlier cancer detection and more effective treatment?

A recent trial involving nine Canadian medical centers compared the results of a limited screening strategy for unprovoked clot patients with the outcomes of a more extensive approach that added CT scans of the abdomen and pelvis. Cleveland Clinic oncologist Alok Khorana, MD, discusses the trial’s findings and their implications for clinical decisionmaking in a New England Journal of Medicine editorial.

Read Cancer Workup after Unprovoked Clot — Less Is More by Dr. Khorana of Cleveland Clinic’s Department of Hematology and Oncology.

Photo credit: ©Russell Lee

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad